Compare ENTA & GNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ENTA | GNE |
|---|---|---|
| Founded | 1995 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Power Generation |
| Sector | Health Care | Utilities |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 374.6M | 382.1M |
| IPO Year | 2012 | 2011 |
| Metric | ENTA | GNE |
|---|---|---|
| Price | $12.12 | $13.82 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $20.40 | N/A |
| AVG Volume (30 Days) | ★ 147.1K | 45.1K |
| Earning Date | 05-11-2026 | 05-05-2026 |
| Dividend Yield | N/A | ★ 2.18% |
| EPS Growth | ★ 29.93 | N/A |
| EPS | N/A | ★ 0.76 |
| Revenue | $102,814,000.00 | ★ $425,202,000.00 |
| Revenue This Year | $7.76 | $17.49 |
| Revenue Next Year | N/A | $7.07 |
| P/E Ratio | ★ N/A | $18.13 |
| Revenue Growth | ★ 16.48 | N/A |
| 52 Week Low | $4.09 | $13.27 |
| 52 Week High | $17.15 | $28.47 |
| Indicator | ENTA | GNE |
|---|---|---|
| Relative Strength Index (RSI) | 39.11 | 45.84 |
| Support Level | $12.09 | $13.56 |
| Resistance Level | $15.52 | $14.87 |
| Average True Range (ATR) | 0.63 | 0.62 |
| MACD | -0.17 | -0.06 |
| Stochastic Oscillator | 7.62 | 30.00 |
Enanta Pharmaceuticals Inc is a biotechnology company that uses a chemistry-based drug discovery approach to develop small-molecule candidates for virology and immunology applications. It focuses on Virology and Immunology. Its active development programs in virology are focused on respiratory syncytial virus, or RSV, and SARS-CoV-2, and Hepatitis B virus. In immunology, the company is engaged in designing and developing potent and selective, oral small molecule inhibitors for the treatment of type 2 inflammatory disease. The company has collaborated with AbbVie, which markets its protease inhibitor paritaprevir, with additional inhibitors in development. The company generates the majority revenue in the form of royalty revenue.
Genie Energy Ltd, through its subsidiaries, operates as a retail energy provider. It serves two reportable business segments: Genie retail energy, or GRE, and Genie renewables. The Genie retail energy segment resells energy to residential and commercial consumers in the Eastern and Midwestern United States through its portfolio of various retail energy providers. The Genie renewables segment holds controlling interests in various companies engaged in the manufacturing of solar panels, solar installation design, and solar energy project management. It generates the majority of its revenue from the Genie retail energy segment.